Sunopta Raises 2025 Revenue Forecast to $788-$805 Million

Published 1 hours agoSTKL

Sunopta Raises 2025 Revenue Forecast to $788-$805 Million

Sunopta, Inc. has updated its revenue guidance for 2025, increasing its expectations to a range of $788 million to $805 million. The company is also targeting gross margins between 18% and 19%. This adjustment showcases Sunopta's confidence in its ongoing strategic initiatives and its positioning within its market.

Currently, Sunopta's stock is trading at $4.75, as of the latest update. The stock showed no significant change from its previous closing price, moving just $0.01. Trading has maintained a volume of 1,208,038, with the stock price holding steady between the intraday high and low of $4.75.

This revised forecast underlines Sunopta's strategy to enhance profitability through focused growth plans, reflecting a solid belief in their future performance. Reuters reported that the company aims to seize opportunities in the market to drive this anticipated growth. Although precise steps have not been detailed, the guidance offers insight into the company's planned trajectory.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Argenx Reports Revenue Growth Amid Q1 Financial Challenges

Argenx Reports Revenue Growth Amid Q1 Financial Challenges

13 minutes agoARGX

Argenx has showcased strong first-quarter performance in 2025, reflecting a continued upward trend in revenue. The company marked nine consecutive quarters of revenue growth, with a notable 34% increase in patients using its VYVGART subcutaneous treatment in the U.S. Additionally, Argenx expanded its global footprint by enrolling over 2,700 patients in China for the therapy within just three months. Despite these milestones, Argenx faced several hurdles during the same period. The company reported a net cash burn of $75 million in Q1, highlighting financial strains as expenditures outpaced income. Furthermore, it halted development efforts in ANCA-associated vasculitis due to identified risks. Nevertheless, Argenx is advancing its regulatory goals with plans to seek FDA approval for a pre-filled syringe version of VYVGART by June 2025. Moving forward, Argenx has outlined plans to address its financial pressures, anticipating expenses for research, development, and administrative operations to reach approximately $2.5 billion for the year. The company, according to Reuters, seeks to achieve sustainable profitability in 2025 by refining its strategic initiatives and leveraging its expanding global presence.

Veracyte Posts Strong Fourth Quarter, Unveils 2025 Projections

Veracyte Posts Strong Fourth Quarter, Unveils 2025 Projections

28 minutes agoVCYT

Veracyte, Inc. has reported impressive financial results for the fourth quarter and the full year of 2024. Notably, the company's revenue surged 21% in the fourth quarter to $118.6 million, driven by a 24% rise in testing revenue reaching $112.2 million. Among the standouts, the Decipher test revenue soared by 44%, while the Afirma test revenue saw a modest 4% increase. Adjusted EBITDA came in at $26.1 million, or 22% of revenue. For the entire 2024, Veracyte recorded a total revenue increase of 23%, amounting to $445.8 million. Testing revenue for the year jumped by 28% to $419.0 million, with Decipher test revenue climbing 43% and Afirma test revenue increasing by 14%. The company's adjusted EBITDA totaled $91.9 million, representing 20.6% of its revenue. These figures have been highlighted in Veracyte's recent release, as reported by investor.veracyte.com. Looking ahead to 2025, Veracyte projects testing revenue of $470 million to $480 million, reflecting a growth forecast of 12% to 15%, adjusting for the paused Envisia test. The company also anticipates an adjusted EBITDA margin of approximately 21.6% of revenue. In terms of strategy, Veracyte plans to expand its Decipher test into the metastatic prostate cancer market in the first half of 2025. Furthermore, the Afirma test will continue to target growth by increasing penetration in existing accounts and acquiring new customers, as noted by ng.investing.com. These initiatives highlight Veracyte's focus on enhancing its diagnostic offerings and fostering sustained growth.

Payoneer Withdraws Annual Guidance Amid Trade Uncertainties

Payoneer Withdraws Annual Guidance Amid Trade Uncertainties

58 minutes agoPAYO

Payoneer Global Inc. has recently taken the significant step of withdrawing its financial guidance for 2025. This decision, attributed to prominent trade uncertainties, influenced the company's stock, which closed at $6.05 on May 7, 2025, resulting in a market capitalization of approximately $2.88 billion. This unexpected move comes after various analyst ratings and assessments. Keefe, Bruyette & Woods downgraded their rating for Payoneer to 'Market Perform' in December 2024 but retained a $12 price target. Meanwhile, in April 2024, Needham maintained a 'Buy' rating, albeit lowering their price target from $8.00 to $7.00, acknowledging strong e-commerce activity and solid product performance. Despite the current volatility, Payoneer reported strong financial results in previous quarters, including a 19% increase in total revenue for the third quarter of 2024. The company is also advancing its strategic acquisition of a Chinese payment service provider, anticipated to finalize within the first half of 2025. These strategic steps are expected to enhance Payoneer's market positioning during this uncertain period.

Sunopta Raises 2025 Revenue Forecast to $788-$805 Million

Sunopta Raises 2025 Revenue Forecast to $788-$805 Million

1 hours agoSTKL

Sunopta, Inc. has updated its revenue guidance for 2025, increasing its expectations to a range of $788 million to $805 million. The company is also targeting gross margins between 18% and 19%. This adjustment showcases Sunopta's confidence in its ongoing strategic initiatives and its positioning within its market. Currently, Sunopta's stock is trading at $4.75, as of the latest update. The stock showed no significant change from its previous closing price, moving just $0.01. Trading has maintained a volume of 1,208,038, with the stock price holding steady between the intraday high and low of $4.75. This revised forecast underlines Sunopta's strategy to enhance profitability through focused growth plans, reflecting a solid belief in their future performance. Reuters reported that the company aims to seize opportunities in the market to drive this anticipated growth. Although precise steps have not been detailed, the guidance offers insight into the company's planned trajectory.